Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Valneva SE Sponsored ADR (NASDAQ:VALN)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $8.41, but opened at $8.83. Valneva shares last traded at $8.8050, with a volume of 4,199 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wall Street Zen downgraded Valneva from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Valneva in a report on Wednesday, October 8th. Finally, Guggenheim reduced their price objective on Valneva from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, September 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Price Performance

The company has a current ratio of 1.78, a quick ratio of 1.36 and a debt-to-equity ratio of 0.72. The business’s fifty day moving average is $8.87 and its 200 day moving average is $8.65. The company has a market cap of $719.02 million, a P/E ratio of -5.80 and a beta of 1.83.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Thursday, November 20th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.31). The firm had revenue of $34.01 million for the quarter, compared to the consensus estimate of $48.85 million. Valneva had a negative net margin of 57.81% and a negative return on equity of 59.44%. As a group, sell-side analysts anticipate that Valneva SE Sponsored ADR will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Valneva

Several institutional investors have recently added to or reduced their stakes in the business. VSM Wealth Advisory LLC increased its stake in shares of Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,000 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Valneva during the 3rd quarter valued at approximately $124,000. Marex Group plc bought a new position in Valneva in the 2nd quarter worth approximately $64,000. Finally, Frazier Life Sciences Management L.P. bought a new position in Valneva in the 2nd quarter worth approximately $8,240,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.